Jasper Therapeutics, Inc. ( (JSPR) ) has released its Q4 earnings. Here is a breakdown of the information Jasper Therapeutics, Inc. presented to its investors.
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of briquilimab, an innovative antibody therapy aimed at treating mast cell-driven diseases like chronic urticaria and asthma.
In its latest earnings report, Jasper Therapeutics highlighted significant progress in its clinical trials, particularly with briquilimab, showcasing promising results in treating chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). The company is poised to advance briquilimab into further pivotal trials, reflecting its commitment to addressing unmet medical needs in mast cell diseases.
The financial results for 2024 reveal a net loss of $71.3 million, with research and development expenses amounting to $55.8 million, underscoring the company’s intensive investment in clinical trials. Despite the financial loss, Jasper maintains a cash reserve of $71.6 million, providing a stable foundation for ongoing research efforts.
Jasper’s strategic focus includes the commencement of a Phase 2b study for briquilimab in CSU, with additional data expected mid-2025 from various study cohorts. The company is also expanding its research into asthma with the ETESIAN study, aiming to establish proof-of-concept for briquilimab in broader respiratory conditions.
Looking ahead, Jasper Therapeutics remains optimistic about briquilimab’s potential to transform treatment paradigms for mast cell-driven diseases, with upcoming clinical milestones expected to further validate its therapeutic efficacy and safety profile.